Novo Nordisk companions with OpenAI to AI-power drug growth

Danish pharmaceutical firm Novo Nordisk has partnered with OpenAI to assist drug analysis and growth. By way of the partnership, Novo Nordisk stated it plans to deploy superior synthetic intelligence (AI) capabilities to analyse complicated datasets, determine promising drug candidates and scale back the time required to maneuver from analysis to affected person.

The corporate stated its use of AI has been structured with strict knowledge safety, governance and human oversight to make sure moral and compliant use. This newest partnership is being positioned as a key a part of the corporate’s technique to make use of AI to rework healthcare and allow it to deliver new and higher therapy choices to sufferers sooner.

In 2024, a break-out session run throughout its Capitals Market Day introduced Novo Nordisk’s technique, discussing the way it makes use of knowledge science and AI and its future plans. The presentation reveals that the corporate arrange an AI centre of excellence in 2021, and had begun ramping up funding in excessive efficiency computing and graphics processor items (GPUs) by 2023. The corporate stated it has deployed a knowledge pool known as FounData, the place all knowledge from accomplished scientific trials are pooled and ready for insights-generation.

It has additionally deployed NovoScribe, an AI-powered platform constructed utilizing MongoDB Atlas Vector Search, Amazon Bedrock and LangChain to automate and speed up the creation of scientific research reviews. Novo Nordisk stated NovoScribe reduces the time to regulatory submissions.

On the time, the corporate stated exterior partnerships and collaborations would proceed to play an necessary position in reaching its AI ambitions.

Earlier this 12 months, Christos Nicolaou, a senior scientific director at Novo Nordisk, posted on LinkedIn that the corporate has now joined Ligand-AI, a brand new mission funded by the EU public-private partnership, Revolutionary Well being Initiative (IHI).

Within the put up, he stated the mission’s aim is to generate top quality, giant, open datasets of protein-ligand interactions for hundreds of proteins. “Within the spirit of open science collaboration, these datasets might be shared and used to implement fashions and strategies to enhance AI-driven drug discovery,” he stated.

This newest partnership with OpenAI builds on expertise partnerships it has with AWS, Microsoft, Google and Hugging Face, in addition to its present collaboration with OpenAI.

“This partnership is one necessary step in positioning Novo Nordisk to steer within the subsequent period of healthcare,” stated Mike Doustdar, president and CEO of Novo Nordisk. “There are tens of millions of individuals dwelling with weight problems and diabetes who want therapy choices, and we all know there are therapies nonetheless ready to be found that would change their lives.

“Integrating AI in our on a regular basis work provides us the flexibility to analyse datasets at a scale that was beforehand unattainable, determine patterns we couldn’t see, and take a look at hypotheses sooner than ever. This implies discovering new therapies and bringing them to market sooner than ever earlier than.”

OpenAI stated it will be aiding Novo Nordisk in upskilling the corporate’s international workforce and enhancing AI literacy. By way of the partnership OpenAI’s capabilities will even be used to enhance effectivity in manufacturing, provide chain and distribution, and company operations. The corporate is beginning pilot programmes throughout analysis and growth, and manufacturing and industrial operations, with full integration by the top of 2026.